Compare ASTRAZENECA PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NATCO PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NATCO PHARMA ASTRAZENECA PHARMA/
NATCO PHARMA
 
P/E (TTM) x 73.2 17.0 429.9% View Chart
P/BV x 22.2 2.7 825.9% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 ASTRAZENECA PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
NATCO PHARMA
Mar-19
ASTRAZENECA PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278849 150.5%   
Low Rs883557 158.5%   
Sales per share (Unadj.) Rs228.4573.8 39.8%  
Earnings per share (Unadj.) Rs10.4176.0 5.9%  
Cash flow per share (Unadj.) Rs16.3198.2 8.2%  
Dividends per share (Unadj.) Rs06.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs98.8842.7 11.7%  
Shares outstanding (eoy) m25.0036.50 68.5%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.71.2 386.1%   
Avg P/E ratio x104.24.0 2,609.6%  
P/CF ratio (eoy) x66.43.5 1,873.1%  
Price / Book Value ratio x10.90.8 1,311.1%  
Dividend payout %03.6 0.0%   
Avg Mkt Cap Rs m27,00825,660 105.3%   
No. of employees `0001.45.0 27.4%   
Total wages/salary Rs m1,5353,559 43.1%   
Avg. sales/employee Rs Th4,210.94,225.3 99.7%   
Avg. wages/employee Rs Th1,132.2718.0 157.7%   
Avg. net profit/employee Rs Th191.11,295.9 14.7%   
INCOME DATA
Net Sales Rs m5,71020,945 27.3%  
Other income Rs m1231,302 9.4%   
Total revenues Rs m5,83322,247 26.2%   
Gross profit Rs m4637,948 5.8%  
Depreciation Rs m147810 18.2%   
Interest Rs m0193 0.0%   
Profit before tax Rs m4388,247 5.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,823 9.8%   
Profit after tax Rs m2596,424 4.0%  
Gross profit margin %8.137.9 21.4%  
Effective tax rate %40.822.1 184.8%   
Net profit margin %4.530.7 14.8%  
BALANCE SHEET DATA
Current assets Rs m3,20923,472 13.7%   
Current liabilities Rs m2,0707,287 28.4%   
Net working cap to sales %20.077.3 25.8%  
Current ratio x1.63.2 48.1%  
Inventory Days Days7292 78.5%  
Debtors Days Days3588 39.6%  
Net fixed assets Rs m79018,648 4.2%   
Share capital Rs m50365 13.7%   
"Free" reserves Rs m2,41934,525 7.0%   
Net worth Rs m2,46930,760 8.0%   
Long term debt Rs m00-   
Total assets Rs m4,60543,031 10.7%  
Interest coverage xNM43.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.5 254.7%   
Return on assets %5.615.4 36.6%  
Return on equity %10.520.9 50.2%  
Return on capital %17.727.4 64.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30011,536 2.6%   
Fx outflow Rs m2,0152,939 68.6%   
Net fx Rs m-1,7158,597 -20.0%   
CASH FLOW
From Operations Rs m886,688 1.3%  
From Investments Rs m-94-6,122 1.5%  
From Financial Activity Rs mNA-509 0.0%  
Net Cashflow Rs m-666 -8.6%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 0.3 7.8 3.8%  
FIIs % 15.7 16.6 94.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.0 35.0%  
Shareholders   12,856 25,395 50.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Volatile Day for Indian Indices: Sensex Ends 131 Points Lower Post Rebound; Telecom and Auto Stocks Bleed(Closing)

It was a volatile day for India share markets today. The benchmark indices opened higher but turned volatile.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Mar 27, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - NATCO PHARMA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS